Multitarget drugs of plants origin acting on alzheimer's disease

Current Medicinal Chemistry

Volumn 20, Issue 13, 2013, Pages 1686-1693

  Russo, P ^a   Frustaci, A ^a   Bufalo, A Del ^a   Fini, M ^a   Cesario, A ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer's disease; Cholinergic system; Crocus sativus; Drug discovery and development; Galantamine; Ginkgo biloba; Huperzia serrata; Multitargets; NAChR; Nicotine; Plant drug; Salvia species; Systems biology

Indexed keywords

ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMYLOID BETA PROTEIN; BILOBALIDE; CAROTENOID; CHOLINESTERASE INHIBITOR; CROCIN; CROCUS SATIVUS EXTRACT; DONEPEZIL; DOPAMINE; ESARINE; FLAVONOID GLYCOSIDE; GALANTAMINE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; HUPERZINE A; KAEMPFEROL; NITRIC OXIDE; NOOTROPIC AGENT; PHYSOSTIGMINE; PLANT MEDICINAL PRODUCT; QUERCETIN; RIVASTIGMINE; SEROTONIN; TACRINE; TERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CHEMICAL COMPOSITION; CLINICAL TRIAL (TOPIC); CROCUS SATIVUS; CRYSTAL STRUCTURE; DEMENTIA; DRUG BINDING SITE; DRUG EFFICACY; DRUG METABOLISM; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GINKGO BILOBA; HUMAN; HUPERZIA; HUPERZIA SERRATA; IC 50; IN VITRO STUDY; MEDICINAL PLANT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHAGOCYTOSIS; SALVIA; SITE DIRECTED MUTAGENESIS;

ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL AGENTS; CHOLINESTERASE INHIBITORS; CROCUS; DRUG DISCOVERY; GALANTAMINE; GALANTHUS; GINKGO BILOBA; HUMANS; HUPERZIA; NEUROPROTECTIVE AGENTS; PHYSOSTIGMINE; PLANT EXTRACTS; PLANTS; SALVIA; SESQUITERPENES;

EID: 84877962244     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320130008     Document Type: Article

References (75)

1. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet, 2011, 377, 1019-1031.
2. Huang, Y.; Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell, 2012, 148, 1204-1222.
3. Parri, R.H.; Dineley, T.K. Nicotinic acetylcholine receptor interaction with beta-amyloid: Molecular, cellular, and physiological consequences. Curr. Alzheimer Res., 2010, 7, 27-39.
4. Parri, H.R.; Hernandez, C.M.; Dineley, K.T. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem. Pharmacol., 2011, 82, 931-942.
5. Hernandez, C.M.; Dineley, K.T. α7 nicotinic acetylcholine receptors in Alzheimer's disease: Neuroprotective, neurotrophic or both? Curr. Drug Targets, 2012, 13, 613-622.
6. Schliebs, R.; Arendt, T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res., 2011, 221, 555-563.
7. Cameron, B.; Landreth, G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis., 2010, 37, 503-509.
8. Wee Yong, V. Inflammation in neurological disorders: A help or a hindrance? Neuroscientist, 2010, 16, 408-420.
9. Eikelenboom, P.; van Exel, E.; Hoozemans, J.J.; Veerhuis, R.; Rozemuller, A.J.; van Gool, W.A. Neuroinflammation-an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener. Dis., 2010, 7, 38-41.
10. Gilboa-Geffen, A.; Hartmann, G.; Soreq, H. Stressing hematopoiesis and immunity: An acetylcholinesterase window into nervous and immune system interactions. Front. Mol. Neurosci., 2012, 5, 30, doi: 10.3389/fnmol.2012.00030.
11. Nicolussi, E.M.; Huck, S.; Lassmann, H.; Bradl, M. The cholinergic anti-inflammatory system limits T cell infiltration into the neurodegenerative CNS, but cannot counteract complex CNS inflammation. Neurobiol. Dis., 2009, 35, 24-31.
12. Herrmann, N.; Chau, S.A.; Kircanski, I.; Lanctôt, K.L. Current and emerging drug treatment options for Alzheimer's disease: A systematic review. Drugs, 2011, 71, 2031-2065.
13. Danysz, W.; Parsons, C.G. Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine-searching for the connections. Br. J. Pharmacol., 2012, 167, 324-352.
14. Hubbard, R.E.; O'Mahony, M.S.; Woodhouse, K.W. Medication prescribing in frail older people. Eur. J. Clin. Pharmacol., 2012, Sep 11, doi: 10.1007/s00228-012-1387-2.
15. Patterson, S.M.; Hughes, C.; Kerse, N.; Cardwell, C.R.; Bradley, M.C. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev., 2012, 5, Art. No.: CD008165. doi:10.1002/14651858. CD008165.pub2.
16. Patyar, S.; Prakash A.; Medhi, B. Dual inhibition: A novel promising pharmacological approach for different disease conditions. J. Pharm. Pharmacol., 2011, 63, 459-471.
17. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets, 2011, 12, 122-132.
18. Chen, J.Q.; Xie, J.H.; Bao, D.H.; Liu, S.; Zhou, Q.L. Total synthesis of (-)-galanthamine and (-)-lycoramine via catalytic asymmetric hydrogenation and intramolecular reductive Heck cyclization. Org. Lett., 2012, 14, 2714-2717.
19. Thomsen, T.; Bickel, U.; Fischer, J.P.; Kewitz, H. Stereoselectivity of cholinesterase inhibition by galantamine and tolerance in humans. Eur. J. Clin. Pharm., 1990, 39, 603-605.
20. Samochocki, M.; Höffle, A.; Fehrenbacher, A.; Jostock, R.; Ludwig, J.; Christner, C.; Radina, M.; Zerlin, M.; Ullmer, C.; Pereira, E.F.; Lübbert, H.;, Albuquerque, E.X.; Maelicke, A Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther., 2003, 305, 1024-1036.
21. Samochocki, M.; Zerlin, M.; Jostock, R.; Kormelink, P.J.G.; Luyten, W.H.M.L.; Albuquerque, E.X.; Maelicke, A. Galantamine is an allosterically potentiating ligand of the human α4β2 nAChR. Acta Neurol. Scand., 2000, 176, 68-73.
22. Pilger, C.; Bartolucci, C.; Lamba, D.; Tropsha, A.; Fels, G. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. J. Mol. Graph. Model., 2001, 19 288-296, and 374-378.
23. Ludwig, J.; Höffle-Maas, A.; Samochocki, M.; Luttmann, E.; Albuquerque, E.X.; Fels, G.; Maelicke, A. Localization by sitedirected mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain. J. Recept. Signal Transduct. Res., 2010, 30, 469-483.
24. Pereira, E.F.R.; Alkondon, M.; Reinhardt, S.; Maelicke, A.; Peng, X.; Lindstrom, J.; Whiting, P.; Albuquerque, E.X. Physostigmine and galanthamine: Probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J. Pharmacol. Exp. Ther., 1994, 270, 768-778.
25. Monod, J.; Wyman, J.; Changeux, J.P. On the nature of allosteric transitions: A plausible model. J. Mol. Biol., 1965, 12, 88-118.
26. Taly, A.; Corringer, P.J.; Guedin, D.; Lestage. P.; Changeux, J.P. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov., 2009, 8, 733-750.
27. Russo, P.; Taly. A. α7-Nicotinic acetylcholine receptors: An old actor for new different roles. Curr. Drug Targets, 2012, 13, 574-578.
28. Maelicke, A. Pharmacokinetic rationale for switching from donepezil to galantamine. Clin. Ther., 2001, 23 Suppl A, A8-12.
29. Takata, K.; Kitamura, Y.; Saeki, M.; Terada, M.; Kagitani, S.; Kitamura, R.; Fujikawa, Y.; Maelicke, A, .; Tomimoto, H.; Taniguchi, T.; Shimohama, S. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J. Biol. Chem., 2010, 285, 40180-40191.
30. Coelho, F.; Birks, J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev., 2001, 2, CD001499.
31. Zhang, H.Y. New insights into huperzine A for the treatment of Alzheimer's disease. Acta Pharmacol. Sin., 2012, 33, 1170-1175.
32. Liang, Y.Q.; Tang, X.C. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci. Lett., 2004, 361, 56-59.
33. Desilets, A.R.; Gickas, J.J.; Dunican, K.C Role of huperzine A in the treatment of Alzheimer's disease. Ann. Pharmacother., 2009, 43, 514-518.
34. Hao, Z.; Liu, M.; Liu, Z.; Lv, D. Huperzine A for vascular dementia. Cochrane Database Syst Rev., 2009, 2, CD007365.
35. Eckert, G.P. Traditional used plants against cognitive decline and Alzheimer disease. Front. Pharmacol., 2010, 1, 138.
36. Howes, M.J.; Perry, E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging, 2011, 28, 439-468.
37. Kim, H.G.; Oh, M.S. Herbal medicines for the prevention and treatment of Alzheimer's disease. Curr. Pharm. Des., 2012, 18, 57-75.
38. ntp.niehs.nih.gov/Ntp/About-Ntp//DraftTR578.pdfC
39. Guo, L.; Mei, N.; Liao, W.; Chan, P.C.; Fu, P.P. Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network. OMICS, 2010, 14, 75-90.
40. Gonzalez, F.J.; Yu, A.M. Cytochrome P450 and xenobiotic receptor humanized mice. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 41-64.
41. Chan, P.C.; Xia, Q.S.; Fu, P.P. Ginkgo biloba leave extract: Biological, medicinal, and toxicological effects. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., 2007, 25, 211-44.
42. Fehske, C.J; Leuner, K.; Müller, W.E. Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol. Res., 2009, 60, 68-73.
43. Lautenschlager, NT.; Ihl, R.; Müller, W.E. Ginkgo biloba extract EGb 761® in the context of current developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease: A research perspective. Int. Psychogeriatr., 2012, 24 Suppl 1, S46-50.
44. Vellas, B.; Coley, N.; Ousset, P.J.; Berrut, G.; Dartigues, J.F.; Dubois, B.; Grandjean, H.; Pasquier, F.; Piette, F.; Robert, P.; Touchon, J.; Garnier, P.; Mathiex-Fortunet, H.; Andrieu, S.; for the GuidAge Study Group. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): A randomised placebo-controlled trial. Lancet Neurol., 2012, Sep 5, doi:10.1016/S1474-4422(12)70206-5.
45. Herrschaft, H.; Nacu, A.; Likhachev, S.; Sholomov, I.; Hoerr, R.; Schlaefke, S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J. Psychiatr. Res., 2012, 46, 716-723.
46. Ihl, R.; Tribanek, M.; Bachinskaya, N.; GOTADAY Study Group. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: Results from a randomised controlled trial. Pharmacopsychiatry, 2012, 45, 41-46.
47. Janssen, I.M.; Sturtz, S.; Skipka, G.;, Zentner, A.; Velasco Garrido, M.; Busse, R. Ginkgo biloba in Alzheimer's disease: A systematic review. Wien Med. Wochenschr., 2010, 160, 539-546.
48. Weinmann, S.; Roll, S.; Schwarzbach, C.; Vauth, C.; Willich, S.N. Effects of Ginkgo biloba in dementia: Systematic review and metaanalysis. BMC Geriatr., 2010, 17, 10:14.
49. Snitz, B.E.; O'Meara, E.S.; Carlson, M.C.; Arnold, A.M.; Ives, D.G.; Rapp, S.R.; Saxton, J.; Lopez, O.L.; Dunn, L.O.; Sink, K.M.; DeKosky, S.T; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. JAMA, 2009, 302, 2663-2670.
50. Bäurle, P.; Suter, A.; Wormstall, H. Safety and effectiveness of a traditional ginkgo fresh plant extract-results from a clinical trial. Forsch. Komplementmed., 2009, 16, 156-161.
51. Yancheva, S.; Ihl, R.; Nikolova, G.; Panayotov, P.; Schlaefke, S.; Hoerr, R; GINDON Study Group. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial. Aging Ment. Health, 2009, 13, 183-190.
52. Napryeyenko, O.; Sonnik, G.; Tartakovsky, I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: Analyses of a randomised controlled trial. J. Neurol. Sci., 2009, 283, 224-229.
53. DeKosky, S,T.; Williamson, J.D.; Fitzpatrick, A.L.; Kronmal, R.A.; Ives, D.G.; Saxton, J.A.; Lopez, O.L.; Burke, G.; Carlson, M.C.; Fried, L.P.; Kuller, L.H.; Robbins, J.A.; Tracy, R.P.; Woolard, N.F.; Dunn, L.; Snitz, B.E.; Nahin, R.L.; Furberg, C.D; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA, 2008, 300, 2253-2262.
54. Andrieu, S.; Ousset, P.J.; Coley, N.; Ouzid, M.; Mathiex-Fortunet, H.; Vellas, B; GuidAge study GROUP. GuidAge study: A 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Curr. Alzheimer Res., 2008, 5, 406-415.
55. Sugiura, M.; Shoyama, Y.; Saito, H.; Abe, K. Crocin (crocetin digentiobiose ester) prevents the inhibitory effect of ethanol on longterm potentiation in the dentate gyrus in vivo. J. Pharmacol. Exp. Ther., 1994, 271,703-707.
56. Soeda, S.; Ochiai, T.; Paopong, L.; Tanaka, H.; Shoyama, Y.; Shimeno, H Crocin suppresses tumor necrosis factor-alpha-induced cell death of neuronally differentiated PC-12 cells. Life Sci., 2001, 69, 2887-2898.
57. Papandreou, M.A.; Kanakis, C.D.; Polissiou, M.G.; Efthimiopoulos, S.; Cordopatis, P.; Margarity, M.; Lamari, F.N Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J. Agric. Food Chem., 2006, 54, 8762-8768.
58. Akhondzadeh, S.; Sabet, M.S.; Harirchian, M.H.; Togha, M.; Cheraghmakani, H.; Razeghi, S.; Hejazi, S.Sh.; Yousefi, M.H.; Alimardani, R.; Jamshidi, A.; Zare, F.; Moradi, A. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: A 16-week, randomized and placebo-controlled trial. J. Clin. Pharm. Ther., 2010, 35, 581-588.
59. Akhondzadeh, S.; Shafiee Sabet, M.; Harirchian, M.H.; Togha, M.; Cheraghmakani, H.; Razeghi, S.; Hejazi, S.Sh.; Yousefi, M.H.; Alimardani, R.; Jamshidi, A.; Rezazadeh, S.A.; Yousefi, A.; Zare, F.; Moradi, A.; Vossoughi, A. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacol. (Berl)., 2010, 207, 637-643.
60. Perry, N.S.;, Houghton, P.J.; Theobald, A.; Jenner, P.; Perry, E.K. In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J. Pharm. Pharmacol., 2000, 52, 895-902.
61. Savelev, S.U.; Okello, E.J.; Perry, E.K. Butyryl-and acetylcholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother. Res., 2004, 18, 315-324.
62. Kennedy, D.O.; Dodd, F.L.; Robertson, B.C.; Okello, E.J.; Reay, J.L.; Scholey, A.B.; Haskell, C.F. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J. Psychopharmacol., 2011, 25, 1088-1100.
63. Scholey, A.B.; Tildesley, N.T.; Ballard, C.G.; Wesnes, K.A.; Tasker, A.; Perry, E.K.; Kennedy, D.O. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology, 2008, 198, 127-139.
64. Tildesley, N.T.; Kennedy, D.O.; Perry, E.K.; Ballard, C.G.; Savelev, S.; Wesnes, K.A.; Scholey, A.B. Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol. Biochem. Behav., 2003, 75, 669-674.
65. Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. J. Clin. Pharm. Ther., 2003, 28, 53-59.
66. Karenberg, A.; Förstl, H. Dementia in the Greco-Roman world. J. Neurol. Sci., 2006, 244, 5-9.
67. Rattan, R.S. Mechanism of action of insecticidal secondary metabolites of plant origin. Crop Prot., 2010, 29, 913-920.
68. Soloway, S.B. Naturally occurring insecticides. Environ. Health Perspect., 1976, 14, 109-117.
69. Cardinale, A.; Nastrucci, C.; Cesario, A.; Russo, P. Nicotine: Specific role in angiogenesis, proliferation and apoptosis. Crit. Rev. Toxicol., 2012, 42, 68-89.
70. Newhouse, P.A; Potter, A.S.; Dumas, J.A.; Thiel, C.M. Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem. Pharmacol., 2011, 82, 943-951.
71. Hellström-Lindahl, E.; Court, J.; Keverne, J.; Svedberg, M.; Lee, M.; Marutle, A.; Thomas, A.; Perry, E.; Bednar, I.; Nordberg, A. Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur. J. Neurosci., 2004, 19, 2703-2710.
72. Newhouse, P.; Kellar, K.; Aisen, P.; White, H.; Wesnes, K.; Coderre, E.; Pfaff, A.; Wilkins, H.; Howard, D.; Levin, E.D. Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology, 2012, 78, 91-101.
73. Russo, P.; Cesario, A.; Rutella, S.; Veronesi, G.; Spaggiari, L.; Galetta, D.; Margaritora, S.; Granone, P.; Greenberg, D.S. Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment. Curr. Med. Chem., 2011, 18, 91-112.
74. Neri, M.; Bonassi, S.; Russo, P. Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia. Curr. Drug Targets, 2012, 13, 636-343.
75. Russo, P.; Cardinale, A.; Margaritora, S.; Cesario, A. Nicotinic receptor and tobacco-related cancer. Life Sci., 2012, 9(21-22), 1087-1092.